Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadly forms of cancer, with a 5-year relative survival rate of only 13%. To understand cell fate decisions and progression in PDAC, it is crucial to clarify the communication networks between tumor cells.
Recurv Pharma Inc. has developed a novel taxoid compound formulated in an oil-in-water nanoemulsion, named RP-001, as a potential therapeutic approach for the management of pancreatic ductal adenocarcinoma (PDAC), either as a single agent or combined with immune checkpoint inhibitors.
At the recent American Association for Cancer Research (AACR) Special Conference on Advances in Pancreatic Cancer Research, researchers from Cellectar Biosciences Inc. presented preclinical data on [225Ac]CLR-121225 (CLR-225), a novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma.
When used as monotherapy against tumors, small molecules that mimic the SMAC protein and thereby inhibit apoptosis are ineffective. The same is true for inhibitors of BET family proteins. If each therapy on its own does not work, what about the two therapies together?
A novel mRNA drug, 3’UTRMYC1-18 (UTRxM1-18), has demonstrated notable efficacy in preclinical models of aggressive pancreatic cancer, addressing a disease that is often resistant to conventional treatments.
Positive results for Revolution Medicines Inc.’s phase I studies of its lead candidate, the RAS-blocker daraxonrasib for treating pancreatic ductal adenocarcinoma, prompted the company to say it’s time for a phase III study in the aggressive cancer. Revolution said it plans to begin a global, randomized and registrational trial in first-line metastatic disease sometime in the fourth quarter of 2025.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, primarily due to its dense, desmoplastic and immunosuppressive tumor microenvironment (TME) that hinders the efficacy of immune checkpoint inhibitors such as anti-programmed cell death 1 (PD-1).
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive and treatment-resistant cancers, with limited therapeutic options and poor survival rates. The development of targeted therapies that disrupt multiple signaling pathways simultaneously could offer new opportunities to improve outcomes in this disease.
Taking an unconventional path to market for its targeted therapies for RAS-addicted cancers, Revolution Medicines Inc. secured access to $2 billion in capital to build its own global commercial infrastructure, instead of partnering outside the U.S. as it had originally intended. “We’ve concluded that the best way for us to achieve our goals with our rich pipeline is to direct our own global development and commercial strategies and to operationalize these both inside and outside the U.S. through our own organization,” Mark Goldsmith, president and CEO of Revolution Medicines (Revmed), told investors June 24.
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers and needs innovative therapeutic solutions. Patients with PDAC have a 5-year survival rate of about 12%. To address this need, researchers have developed a Drosophila PDAC model harboring the genetic alterations in the KRAS, CDKN2A, TP53 and SMAD4 genes (4-hit model), which accounts for the worst and most aggressive PDAC with lower survival rates.
